NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Forecast & News

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics Inc (NASDAQ:KPTI) posted its earnings results on Thursday, February, 13th. The company reported ($0.76) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.10. The firm earned $18.10 million during the quarter, compared to the consensus estimate of $16.48 million. View Karyopharm Therapeutics' Earnings History.

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Karyopharm Therapeutics.

6 analysts have issued 12 month target prices for Karyopharm Therapeutics' shares. Their forecasts range from $5.00 to $37.00. On average, they expect Karyopharm Therapeutics' share price to reach $22.33 in the next year. This suggests a possible upside of 45.2% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.

Media stories about KPTI stock have been trending somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Karyopharm Therapeutics earned a news sentiment score of 1.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Karyopharm Therapeutics.

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Micron Technology (MU), Exelixis (EXEL), Alibaba Group (BABA), Caladrius Biosciences (CLBS), GW Pharmaceuticals PLC- (GWPH), Sorrento Therapeutics (SRNE) and Advanced Micro Devices (AMD).

Karyopharm Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (5.14%), Delphi Management Partners VIII L.L.C. (3.60%), Candriam Luxembourg S.C.A. (1.35%), FMR LLC (1.01%), Goldman Sachs Group Inc. (0.89%) and Emerald Advisers LLC (0.80%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

KPTI stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, J. Goldman & Co LP, Candriam Luxembourg S.C.A., Schonfeld Strategic Advisors LLC, UBS Group AG, FMR LLC and Citigroup Inc.. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.

KPTI stock was bought by a variety of institutional investors in the last quarter, including Delphi Management Partners VIII L.L.C., Parkman Healthcare Partners LLC, Fairmount Funds Management LLC, Marshall Wace LLP, EAM Investors LLC, Renaissance Technologies LLC, California Public Employees Retirement System and EAM Global Investors LLC. View Insider Buying and Selling for Karyopharm Therapeutics.

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KPTI stock can currently be purchased for approximately $15.38.